400 million people worldwide suffer from various retinal diseases and nearly half of them suffer from AMD (Age-Related Macular Degeneration).
The only Augmented Reality glasses on the market, with over 40 degrees FOV (Field-of-View), to simulate natural vision!
11x revenue increase YoY
Eyedaptic has received multiple finalist awards across a variety of ophthalmology and technology organizations such as Vision Tank Start-Up Competition and High Tech
400 million people worldwide suffer from various retinal diseases and nearly half of them suffer from AMD (Age-Related Macular Degeneration), which is the leading cause of vision loss for ages over 60.
90% of AMD cases are classified as Dry AMD. The disorder affects patients’ central vision, the fine, detailed segment of our vision that is used for reading or using a computer. This makes everyday tasks for sufferers extremely challenging, especially when many of us are dependent on our phones, computers and other devices.
400M+ people are affected by retinal disease globally
170M+ people are affected by AMD specifically
90% of these people have Dry AMD — where there is currently no cure or therapy
Our USA pilot partnership with Vispero enables quicker servicing of the market and scalability, and lower expense overhead.
Gross Margins between 60% to 70% through low vision specialists, optometrists, and distributors.
Through the development of software-driven smart glasses and leveraging the power of augmented reality (AR) technology, Eyedaptic improves the vision of those suffering from retinal disorders including age-related macular degeneration.
Our proprietary software integrates with the real world to enhance images, remap pixels and this adaptive system has an autonomous user interface design with machine learning.
Smart eyewear with proprietary software that instantly enhances vision
Non-invasive, state-of-the-art, visual assistive AR (augmented reality) technology
Simulates natural vision and optimizes useful peripheral vision
Customizes and adapts to users needs, habits and environment
Proprietary software
Integrates with the real world & wearable for mobility
U.S. FDA Class I Exempt Device
7 Patents Pending
Our one-of-a-kind AR visual aid solution helps AMD patients to perform everyday tasks and remain independent.
• Time to Complete Tasks Improved 35% - 50%
• Over 5X Improvement With Eyedaptic
• Achieved a Doubling of Visual Acuity, on Average, with Eyedaptic
The hearing aid market is worth over $8B today and is projected to reach $14.45B by 2026.
Both industries have a similar market size, demographics and are direct consumer payable.
We aim to develop a direct to consumer model, similar to the hearing aid industry.
Hearing aids can cost from $2,000 to over $8,000 per pair – paid by the consumer.
Patents Filed
EYE1 Beta
Testing
Clinical
Trial
EYE2 Beta
Testing
Pilot Launch
EYE3 Beta
Testing
USA Launch
EYE4 Beta testing & Premier SW
Tech Coast Angels
Largest & most active Angel group in the USA
New York Angels
Seed capital angel investors based in New York City
Band of Angels
Oldest Angel Group in the USA
Members of the American Retina Forum
Leading young MDs who are Ophthalmologists and Retina Specialists